Fig. 8: MEF2A knockdown promoted cetuximab sensitivity in CRC xenograft nude mice. | Cell Death Discovery

Fig. 8: MEF2A knockdown promoted cetuximab sensitivity in CRC xenograft nude mice.

From: N6-methyladenosine modification of MEF2A weakens cetuximab sensitivity in colorectal cancer via PD-L1/SOX12 axis

Fig. 8

CRC cells (SW480 or LoVo) with stable MEF2A knockdown were subcutaneously injected into nude mice, before cetuximab treatment. A Tumors formed in each group. B Tumor size. C Tumor weight. D Immunohistochemistry for observing Ki-67 expression in tumor tissues. Scale bar: 50 μm. E TUNEL staining for assessing apoptosis in tumor tissues. Scale bar: 50 μm. F Immunohistochemistry for measuring MEF2A expression in tumor tissues. Scale bar: 50 μm. G MEF2A, PD-L1, and SOX12 protein levels in tumor tissues were determined using western blot. H The protein expressions of cleaved caspase-3, uncleaved PARP, cyclin D1, cyclin E1, and CDK2 in tumor tissues were tested by western blot. All bar chart analysis of western blot is a repeated experiment three times. *p < 0.05, **p < 0.01, and ***p < 0.001.

Back to article page